



- 14.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
- 14.3 Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE

**16 HOW SUPPLIED/STORAGE AND HANDLING**

---

**17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.







warfarin. One approach is to discontinue ELIQUIS and begin both a parenteral anticoagulant and warfarin at the time the next dose of ELIQUIS would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.

*Switching from ELIQUIS to anticoagulants other than warfarin (oral or parenteral):* Discontinue ELIQUIS and begin taking the new anticoagulant other than warfarin at the usual time of the next dose of ELIQUIS.

*Switching from anticoagulants other than warfarin (oral or parenteral) to ELIQUIS:* Discontinue the anticoagulant other than warfarin and begin taking ELIQUIS at the usual time of the next dose of the anticoagulant other than warfarin.

## **2.5 Strong Dual Inhibitors of CYP3A4 and P-glycoprotein**

For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose by 50% when ELIQUIS is coadministered with drugs that are strong dual inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin) [see *Clinical Pharmacology (12.3)*].

In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with strong dual inhibitors of CYP3A4 and P-gp [see *Drug Interactions (7.1)*].

## **2.6 Administration Options**

For patients who are unable to swallow whole tablets, 5 mg and 2.5 mg ELIQUIS tablets may be crushed and suspended in water, 5% dextrose in water (D5W), or apple juice, or mixed with applesauce and promptly administered orally [see *Clinical Pharmacology (12.3)*]. Alternatively, ELIQUIS tablets may be crushed and suspended in 60 mL of water or D5W and promptly delivered through a nasogastric tube [see *Clinical Pharmacology (12.3)*].

Crushed ELIQUIS tablets are stable in water, D5W, apple juice, and applesauce for up to 4 hours.

## **3 DOSAGE FORMS AND STRENGTHS**

- 2.5 mg, yellow, round, biconvex, film-coated tablets with “893” debossed on one side and “2½” on the other side.
- 5 mg, pink, oval-shaped, biconvex, film-coated tablets with “894” debossed on one side and “5” on the other side.

## 4 CONTRAINDICATIONS

ELIQUIS is contraindicated in patients with the following conditions:

- Active pathological bleeding [*see Warnings and Precautions (5.2) and Adverse Reactions (6.1)*]
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [*see Adverse Reactions (6.1)*]

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation

Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [*see Dosage and Administration (2.4) and Clinical Studies (14.1)*].

### 5.2 Bleeding

ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding [*see Dosage and Administration (2.1) and Adverse Reactions (6.1)*].

Concomitant use of drugs affecting hemostasis increases the risk of bleeding. These include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs) [*see Drug Interactions (7.3)*].

Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.

#### *Reversal of Anticoagulant Effect*

A specific antidote for ELIQUIS is not available, and there is no established way to reverse bleeding in patients taking ELIQUIS. The pharmacodynamic effect of ELIQUIS can be expected to persist for at least 24 hours after the last dose, i.e., for about two drug half-lives. Use of procoagulant reversal agents, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate or recombinant factor VIIa, may be considered but has not been evaluated in clinical studies [*see Clinical Pharmacology (12.2)*]. When PCCs are used,

monitoring for the anticoagulation effect of apixaban using a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity is not useful and is not recommended. Activated oral charcoal reduces absorption of apixaban, thereby lowering apixaban plasma concentration [*see Overdosage (10)*].

Hemodialysis does not appear to have a substantial impact on apixaban exposure [*see Clinical Pharmacology (12.3)*]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. There is no experience with systemic hemostatics (desmopressin and aprotinin) in individuals receiving apixaban and they are not expected to be effective as a reversal agent.

### **5.3 Spinal/Epidural Anesthesia or Puncture**

When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.

The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours.

Monitor patients frequently for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, bowel, or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.

### **5.4 Patients with Prosthetic Heart Valves**

The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves. Therefore, use of ELIQUIS is not recommended in these patients.



## **5.5 Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy**

Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

## **6 ADVERSE REACTIONS**

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.

- Increased risk of thrombotic events after premature discontinuation [*see Warnings and Precautions (5.1)*]
- Bleeding [*see Warnings and Precautions (5.2)*]
- Spinal/epidural anesthesia or puncture [*see Warnings and Precautions (5.3)*]

### **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

#### *Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation*

The safety of ELIQUIS was evaluated in the ARISTOTLE and AVERROES studies [*see Clinical Studies (14)*], including 11,284 patients exposed to ELIQUIS 5 mg twice daily and 602 patients exposed to ELIQUIS 2.5 mg twice daily. The duration of ELIQUIS exposure was  $\geq 12$  months for 9375 patients and  $\geq 24$  months for 3369 patients in the two studies. In ARISTOTLE, the mean duration of exposure was 89 weeks ( $>15,000$  patient-years). In AVERROES, the mean duration of exposure was approximately 59 weeks ( $>3000$  patient-years).

The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively.

























































**Table 12: Summary of Key Efficacy Analysis Results During the Intended Treatment Period for Patients Undergoing Elective Knee Replacement Surgery\***

Events during 12-day treatment period	ADVANCE-1			ADVANCE-2		
	ELIQUIS 2.5 mg po bid	Enoxaparin 30 mg sc q12h	Relative Risk (95% CI) P-value	ELIQUIS 2.5 mg po bid	Enoxaparin 40 mg sc qd	Relative Risk (95% CI) P-value
<b>Number of Patients</b>	<b>N=1157</b>	<b>N=1130</b>		<b>N=976</b>	<b>N=997</b>	
Total VTE <sup>†</sup> /All-cause death	104 (8.99%) (7.47, 10.79)	100 (8.85%) (7.33, 10.66)	1.02 (0.78, 1.32) NS	147 (15.06%) (12.95, 17.46)	243 (24.37%) (21.81, 27.14)	0.62 (0.51, 0.74) p<0.0001
<b>Number of Patients</b>	<b>N=1599</b>	<b>N=1596</b>		<b>N=1528</b>	<b>N=1529</b>	
All-cause death	3 (0.19%) (0.04, 0.59)	3 (0.19%) (0.04, 0.59)		2 (0.13%) (0.01, 0.52)	0 (0%) (0.00, 0.31)	
PE	16 (1.0%) (0.61, 1.64)	7 (0.44%) (0.20, 0.93)		4 (0.26%) (0.08, 0.70)	0 (0%) (0.00, 0.31)	
Symptomatic DVT	3 (0.19%) (0.04, 0.59)	7 (0.44%) (0.20, 0.93)		3 (0.20%) (0.04, 0.61)	7 (0.46%) (0.20, 0.97)	
<b>Number of Patients</b>	<b>N=1254</b>	<b>N=1207</b>		<b>N=1192</b>	<b>N=1199</b>	
Proximal DVT <sup>‡</sup>	9 (0.72%) (0.36, 1.39)	11 (0.91%) (0.49, 1.65)		9 (0.76%) (0.38, 1.46)	26 (2.17%) (1.47, 3.18)	
<b>Number of Patients</b>	<b>N=1146</b>	<b>N=1133</b>		<b>N=978</b>	<b>N=1000</b>	
Distal DVT <sup>‡</sup>	83 (7.24%) (5.88, 8.91)	91 (8.03%) (6.58, 9.78)		142 (14.52%) (12.45, 16.88)	239 (23.9%) (21.36, 26.65)	

\* Events associated with each endpoint were counted once per subject but subjects may have contributed events to multiple endpoints.

† Total VTE includes symptomatic and asymptomatic DVT and PE.

‡ Includes symptomatic and asymptomatic DVT.

The efficacy profile of ELIQUIS was generally consistent across subgroups of interest for this indication (e.g., age, gender, race, body weight, renal impairment).

### 14.3 Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE

Efficacy and safety of ELIQUIS for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following 6 to 12 months of anticoagulant treatment was derived from the AMPLIFY and AMPLIFY-EXT studies. Both studies were randomized, parallel-group, double-blind trials in patients with symptomatic proximal DVT and/or symptomatic PE. All key

safety and efficacy endpoints were adjudicated in a blinded manner by an independent committee.

### *AMPLIFY*

The primary objective of AMPLIFY was to determine whether ELIQUIS was noninferior to enoxaparin/warfarin for the incidence of recurrent VTE (venous thromboembolism) or VTE-related death. Patients with an objectively confirmed symptomatic DVT and/or PE were randomized to treatment with ELIQUIS 10 mg twice daily orally for 7 days followed by ELIQUIS 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR  $\geq 2$ ) followed by warfarin (target INR range 2.0-3.0) orally for 6 months. Patients who required thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent, and patients with creatinine clearance  $< 25$  mL/min, significant liver disease, an existing heart valve or atrial fibrillation, or active bleeding were excluded from the AMPLIFY study. Patients were allowed to enter the study with or without prior parenteral anticoagulation (up to 48 hours).

A total of 5244 patients were evaluable for efficacy and were followed for a mean of 154 days in the ELIQUIS group and 152 days in the enoxaparin/warfarin group. The mean age was 57 years. The AMPLIFY study population was 59% male, 83% Caucasian, 8% Asian, and 4% Black. For patients randomized to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9%.

Approximately 90% of patients enrolled in AMPLIFY had an unprovoked DVT or PE at baseline. The remaining 10% of patients with a provoked DVT or PE were required to have an additional ongoing risk factor in order to be randomized, which included previous episode of DVT or PE, immobilization, history of cancer, active cancer, and known prothrombotic genotype.

ELIQUIS was shown to be noninferior to enoxaparin/warfarin in the AMPLIFY study for the primary endpoint of recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death over 6 months of therapy (Table 13).

**Table 13: Efficacy Results in the AMPLIFY Study**

	<b>ELIQUIS</b> <b>N=2609</b> <b>n</b>	<b>Enoxaparin/Warfarin</b> <b>N=2635</b> <b>n</b>	<b>Relative Risk</b> <b>(95% CI)</b>
VTE or VTE-related death*	59 (2.3%)	71 (2.7%)	0.84 (0.60, 1.18)
DVT <sup>†</sup>	22 (0.8%)	35 (1.3%)	
PE <sup>†</sup>	27 (1.0%)	25 (0.9%)	
VTE-related death <sup>†</sup>	12 (0.4%)	16 (0.6%)	
VTE or all-cause death	84 (3.2%)	104 (4.0%)	0.82 (0.61, 1.08)
VTE or CV-related death	61 (2.3%)	77 (2.9%)	0.80 (0.57, 1.11)

\* Noninferior compared to enoxaparin/warfarin (P-value <0.0001).

† Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.

In the AMPLIFY study, patients were stratified according to their index event of PE (with or without DVT) or DVT (without PE). Efficacy in the initial treatment of VTE was consistent between the two subgroups.

#### *AMPLIFY-EXT*

Patients who had been treated for DVT and/or PE for 6 to 12 months with anticoagulant therapy without having a recurrent event were randomized to treatment with ELIQUIS 2.5 mg orally twice daily, ELIQUIS 5 mg orally twice daily, or placebo for 12 months. Approximately one-third of patients participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study.

A total of 2482 patients were randomized to study treatment and were followed for a mean of approximately 330 days in the ELIQUIS group and 312 days in the placebo group. The mean age in the AMPLIFY-EXT study was 57 years. The study population was 57% male, 85% Caucasian, 5% Asian, and 3% Black.

The AMPLIFY-EXT study enrolled patients with either an unprovoked DVT or PE at baseline (approximately 92%) or patients with a provoked baseline event and one additional risk factor for recurrence (approximately 8%). However, patients who had experienced multiple episodes of unprovoked DVT or PE were excluded from the AMPLIFY-EXT study. In the AMPLIFY-EXT study, both doses of ELIQUIS were superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE), or all-cause death (Table 14).

**Table 14: Efficacy Results in the AMPLIFY-EXT Study**

	ELIQUIS 2.5 mg bid N=840	ELIQUIS 5 mg bid N=813	Placebo N=829	Relative Risk (95% CI)	
				ELIQUIS 2.5 mg bid vs Placebo	ELIQUIS 5 mg bid vs Placebo
	n (%)				
Recurrent VTE or all-cause death	32 (3.8)	34 (4.2)	96 (11.6)	0.33 (0.22, 0.48) p<0.0001	0.36 (0.25, 0.53) p<0.0001
DVT*	19 (2.3)	28 (3.4)	72 (8.7)		
PE*	23 (2.7)	25 (3.1)	37 (4.5)		
All-cause death	22 (2.6)	25 (3.1)	33 (4.0)		

\* Patients with more than one event are counted in multiple rows.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### How Supplied

ELIQUIS (apixaban) tablets are available as listed in the table below.

Tablet Strength	Tablet Color/Shape	Tablet Markings	Package Size	NDC Code
2.5 mg	Yellow, round, biconvex	Debossed with “893” on one side and “2½” on the other side	Bottles of 60	0003-0893-21
			Bottles of 180	0003-0893-41
			Hospital Unit-Dose Blister Package of 100	0003-0893-31
5 mg	Pink, oval, biconvex	Debossed with “894” on one side and “5” on the other side	Bottles of 60	0003-0894-21
			Bottles of 180	0003-0894-41
			Hospital Unit-Dose Blister Package of 100	0003-0894-31

### Storage and Handling

Store at 20°C to 25°C (68°F-77°F); excursions permitted between 15°C and 30°C (59°F-86°F) [see USP Controlled Room Temperature].

## 17 PATIENT COUNSELING INFORMATION

Advise patients to read the FDA-approved patient labeling (*Medication Guide*).

Advise patients of the following:

- Not to discontinue ELIQUIS without talking to their physician first.
- That it might take longer than usual for bleeding to stop, and they may bruise or bleed more easily when treated with ELIQUIS. Advise patients about how to recognize bleeding or symptoms of hypovolemia and of the urgent need to report any unusual bleeding to their physician.
- To tell their physicians and dentists they are taking ELIQUIS, and/or any other product known to affect bleeding (including nonprescription products, such as aspirin or NSAIDs), before any surgery or medical or dental procedure is scheduled and before any new drug is taken.
- If the patient is having neuraxial anesthesia or spinal puncture, inform the patient to watch for signs and symptoms of spinal or epidural hematomas [*see Warnings and Precautions (5.3)*]. If any of these symptoms occur, advise the patient to seek emergent medical attention.
- To tell their physicians if they are pregnant or plan to become pregnant or are breastfeeding or intend to breastfeed during treatment with ELIQUIS [*see Use in Specific Populations (8.1, 8.3)*].
- How to take ELIQUIS if they cannot swallow, or require a nasogastric tube [*see Dosage and Administration (2.6)*].
- What to do if a dose is missed [*see Dosage and Administration (2.2)*].

Marketed by:

Bristol-Myers Squibb Company  
Princeton, New Jersey 08543 USA  
and  
Pfizer Inc  
New York, New York 10017 USA

Rotachrom<sup>®</sup> is a registered trademark of Diagnostica Stago.

**MEDICATION GUIDE**  
**ELIQUIS<sup>®</sup>** (ELL eh kwiss)  
**(apixaban)**  
**tablets**

**What is the most important information I should know about ELIQUIS?**

- **For people taking ELIQUIS for atrial fibrillation:**

People with atrial fibrillation (a type of irregular heartbeat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. ELIQUIS lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking ELIQUIS, you may have increased risk of forming a clot in your blood.

**Do not stop taking ELIQUIS without talking to the doctor who prescribes it for you. Stopping ELIQUIS increases your risk of having a stroke.**

ELIQUIS may need to be stopped, if possible, prior to surgery or a medical or dental procedure. Ask the doctor who prescribed ELIQUIS for you when you should stop taking it. Your doctor will tell you when you may start taking ELIQUIS again after your surgery or procedure. If you have to stop taking ELIQUIS, your doctor may prescribe another medicine to help prevent a blood clot from forming.

- **ELIQUIS can cause bleeding** which can be serious and rarely may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting.

You may have a higher risk of bleeding if you take ELIQUIS and take other medicines that increase your risk of bleeding, including:

- aspirin or aspirin-containing products
- long-term (chronic) use of nonsteroidal anti-inflammatory drugs (NSAIDs)
- warfarin sodium (COUMADIN<sup>®</sup>, JANTOVEN<sup>®</sup>)
- any medicine that contains heparin
- selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
- other medicines to help prevent or treat blood clots

Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.

While taking ELIQUIS:

- you may bruise more easily
- it may take longer than usual for any bleeding to stop



**Call your doctor or get medical help right away if you have any of these signs or symptoms of bleeding when taking ELIQUIS:**

- unexpected bleeding, or bleeding that lasts a long time, such as:
  - unusual bleeding from the gums
  - nosebleeds that happen often
  - menstrual bleeding or vaginal bleeding that is heavier than normal
- bleeding that is severe or you cannot control
- red, pink, or brown urine
- red or black stools (looks like tar)
- cough up blood or blood clots
- vomit blood or your vomit looks like coffee grounds
- unexpected pain, swelling, or joint pain
- headaches, feeling dizzy or weak
- **ELIQUIS is not for patients with artificial heart valves.**
- **Spinal or epidural blood clots (hematoma).** People who take a blood thinner medicine (anticoagulant) like ELIQUIS, and have medicine injected into their spinal and epidural area, or have a spinal puncture have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if:
  - a thin tube called an epidural catheter is placed in your back to give you certain medicine
  - you take NSAIDs or a medicine to prevent blood from clotting
  - you have a history of difficult or repeated epidural or spinal punctures
  - you have a history of problems with your spine or have had surgery on your spine

If you take ELIQUIS and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots or bleeding. Tell your doctor right away if you have tingling, numbness, or muscle weakness, especially in your legs and feet.

**What is ELIQUIS?**

ELIQUIS is a prescription medicine used to:

- reduce the risk of stroke and blood clots in people who have atrial fibrillation.
- reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery.
- treat blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism), and reduce the risk of them occurring again.

It is not known if ELIQUIS is safe and effective in children.

### **Who should not take ELIQUIS?**

#### **Do not take ELIQUIS if you:**

- currently have certain types of abnormal bleeding.
- have had a serious allergic reaction to ELIQUIS. Ask your doctor if you are not sure.

### **What should I tell my doctor before taking ELIQUIS?**

#### **Before you take ELIQUIS, tell your doctor if you:**

- have kidney or liver problems
- have any other medical condition
- have ever had bleeding problems
- are pregnant or plan to become pregnant. It is not known if ELIQUIS will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ELIQUIS passes into your breast milk. You and your doctor should decide if you will take ELIQUIS or breastfeed. You should not do both.

Tell all of your doctors and dentists that you are taking ELIQUIS. They should talk to the doctor who prescribed ELIQUIS for you, before you have **any** surgery, medical or dental procedure.

**Tell your doctor about all the medicines you take, including** prescription and over-the-counter medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way ELIQUIS works. Certain medicines may increase your risk of bleeding or stroke when taken with ELIQUIS. See **"What is the most important information I should know about ELIQUIS?"**

Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

### **How should I take ELIQUIS?**

- **Take ELIQUIS exactly as prescribed by your doctor.**
- Take ELIQUIS twice every day with or without food.
- Do not change your dose or stop taking ELIQUIS unless your doctor tells you to.
- If you miss a dose of ELIQUIS, take it as soon as you remember. Do not take more than one dose of ELIQUIS at the same time to make up for a missed dose.
- If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take ELIQUIS.
- Your doctor will decide how long you should take ELIQUIS. **Do not stop taking it without first talking with your doctor. If you are taking ELIQUIS for**

**atrial fibrillation, stopping ELIQUIS may increase your risk of having a stroke.**

- **Do not run out of ELIQUIS. Refill your prescription before you run out.** When leaving the hospital following hip or knee replacement, be sure that you will have ELIQUIS available to avoid missing any doses.
- If you take too much ELIQUIS, call your doctor or go to the nearest hospital emergency room right away.
- Call your doctor or healthcare provider right away if you fall or injure yourself, especially if you hit your head. Your doctor or healthcare provider may need to check you.

### **What are the possible side effects of ELIQUIS?**

- See **“What is the most important information I should know about ELIQUIS?”**
- ELIQUIS can cause a skin rash or severe allergic reaction. Call your doctor or get medical help right away if you have any of the following symptoms:
  - chest pain or tightness
  - swelling of your face or tongue
  - trouble breathing or wheezing
  - feeling dizzy or faint

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of ELIQUIS. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

### **How should I store ELIQUIS?**

Store ELIQUIS at room temperature between 68°F to 77°F (20°C to 25°C).

**Keep ELIQUIS and all medicines out of the reach of children.**

### **General Information about ELIQUIS**

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ELIQUIS for a condition for which it was not prescribed. Do not give ELIQUIS to other people, even if they have the same symptoms that you have. It may harm them.

If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ELIQUIS that is written for health professionals.

For more information, call 1-855-354-7847 (1-855-ELIQUIS) or go to [www.ELIQUIS.com](http://www.ELIQUIS.com).

### **What are the ingredients in ELIQUIS?**

Active ingredient: apixaban.

Inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Marketed by:  
Bristol-Myers Squibb Company  
Princeton, New Jersey 08543 USA  
and  
Pfizer Inc  
New York, New York 10017 USA

COUMADIN<sup>®</sup> is a registered trademark of Bristol-Myers Squibb Pharma Company. All other trademarks are property of their respective companies.

Revised July 2016